Navigation Links
Genzyme Reports Strong First-Quarter Growth
Date:4/23/2008

and Genzyme undertakes no obligation to update or revise the statements.

Genzyme(R), Myozyme(R), Fabrazyme(R), Cerezyme(R), Thyrogen(R), Renagel(R), Renvela(R), Thymoglobulin(R), Synvisc(R), Campath(R) and Clolar(R) are registered trademarks of and Mozobil(TM) and Synvisc-ONE(TM) are unregistered trademarks of Genzyme or its subsidiaries. Aldurazyme(R) is a registered trademark of BioMarin/Genzyme LLC. All rights reserved.

About Genzyme

One of the world's leading biotechnology companies, Genzyme is dedicated to making a major positive impact on the lives of people with serious diseases. Since 1981, the company has grown from a small start-up to a diversified enterprise with more than 10,000 employees in locations spanning the globe and 2007 revenues of $3.8 billion. In 2007, Genzyme was chosen to receive the National Medal of Technology, the highest honor awarded by the President of the United States for technological innovation.

With many established products and services helping patients in nearly 90 countries, Genzyme is a leader in the effort to develop and apply the most advanced technologies in the life sciences. The company's products and services are focused on rare inherited disorders, kidney disease, orthopaedics, cancer, transplant, and diagnostic testing. Genzyme's commitment to innovation continues today with a substantial development program focused on these fields, as well as immune disease, cardiovascular disease, and other areas of unmet medical need.

Conference Call Information

Genzyme will host a conference call today at 11:00 a.m. Eastern to discuss results for the first quarter of 2008. To participate in the call, please dial 773-799-3828 and refer to pass code "Genzyme." A replay of this call will be available by dialing 402-998-1342. This call will also be Webcast live on the investor events section of http://www.genzyme.com. Replays of the call and th
'/>"/>

SOURCE Genzyme Corp.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19

Related biology technology :

1. Genzyme to Build New R&D Center in Beijing
2. Genzyme Provides Update on Myozyme(R) Manufacturing
3. Genzyme Withdraws Bioenvisions European Filing of Evoltra(R) in Elderly AML Patients
4. Genzyme Launches Renvela(R) in the U.S. for Dialysis Patients
5. Genzyme and Isis Announce Hart-Scott-Rodino Approval of Collaboration
6. Genzyme and Isis Announce Strategic Alliance Including Exclusive Worldwide License of Mipomersen
7. BioMarin and Genzyme Restructure Aldurazyme 50/50 Joint Venture
8. Genzyme Receives European CE Mark for Single-Treatment Synvisc-One(TM)
9. Genzyme Announces FDA Approval of Thyrogen(R) for Use in Thyroid Cancer Ablation
10. Genzyme Study of Myozyme(R) for Late-Onset Pompe Patients Meets Co-Primary Efficacy Endpoints
11. Genzyme and Sunway to Collaborate on Gene Therapy Program in China
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/5/2015)... Oakland, CA (PRWEB) May 05, 2015 ... Database technology, today announced that its flagship product, AllegroGraph, ... recent Graph Database Market Update report. AllegroGraph ... by leveraging the W3C industry standards. Graph databases are skyrocketing ... two years, according to a recent DBMS ranking ...
(Date:5/5/2015)... SAN DIEGO , May 5, 2015 /PRNewswire/ ... today announced that David R. Parkinson , ... (NEA), has been appointed to the board of ... twenty years of experience in oncology clinical development, ... that resulted in global approvals of the cancer ...
(Date:5/5/2015)... The Alliance for Clinical Research Excellence ... in the public interest, and Texas-based for-profit San ... Company, have formed a strategic alliance to create a ... across the healthcare and clinical research endeavor. The ... and the public to be clearly heard in this ...
(Date:5/4/2015)... 4, 2015 GliaCure, a privately-held biotechnology ... for neurological and neuropsychiatric disorders based on glial ... Alzheimer,s patients in a Phase 1b clinical trial ... developed as a potential disease-modifying treatment. GliaCure,s innovative ... that it both promotes the clearance of amyloid ...
Breaking Biology Technology:Bloor Research Positions AllegroGraph as a ‘Champion’ in Burgeoning Graph Database Market 2Bloor Research Positions AllegroGraph as a ‘Champion’ in Burgeoning Graph Database Market 3Tocagen Appoints David R. Parkinson, M.D., to the Board of Directors 2Tocagen Appoints David R. Parkinson, M.D., to the Board of Directors 3Tocagen Appoints David R. Parkinson, M.D., to the Board of Directors 4ACRES and San Antonio Express-News Launch Blog on Accountability in Clinical Research 2ACRES and San Antonio Express-News Launch Blog on Accountability in Clinical Research 3ACRES and San Antonio Express-News Launch Blog on Accountability in Clinical Research 4GliaCure Initiates Phase 1b Dosing in Alzheimer's Patients 2
... N.J., Jan. 3 Pharmos Corporation,(Nasdaq: PARS ... initial closing of,a private placement of its 10% ... the Company issued $4,000,000 principal amount of the,Debentures, ... same amount., The purchasers consisted of certain ...
... RUTHERFORD, N.J., Jan. 3 Cambrex,Corporation (NYSE: ... A. Mack,Chairman, President and Chief Executive Officer, will ... Healthcare Conference on January 8, 2008 at,9:00 a.m. ... California., (Logo: http://www.newscom.com/cgi-bin/prnh/20000613/CAMBREXLOGO ), ...
... Holdings, Inc., a fully,integrated critical care biopharmaceutical company, ... will present at the 26th Annual JPMorgan,Healthcare Conference ... PST. The,conference will be held January 7-10 at ... About Ikaria Holdings, Inc., Ikaria Holdings, Inc. ...
Cached Biology Technology:Pharmos Corporation Completes Initial Closing of Private Placement 2
(Date:4/6/2015)... Conn. , Apr. 6, 2015 NXT-ID, ... "Company"), a biometric authentication company focused on the ... has filed provisional patent 62/143028 for ... COMMUNICATIONS AND ENERGY TRANSFER  NXT-ID introduces a ... payments. This patent surrounds the use of miniature ...
(Date:4/2/2015)... GOTHENBURG, Sweden , April 2, 2015 ... for its touch fingerprint sensor FPC1025 from the distributor ... Deliveries will commence during Q2 2015 although the major ... 2015. The sensors will be used by smartphone manufacturers ... of 110 MSEK is included in the communicated revenue ...
(Date:3/31/2015)... NEW YORK , March 31, 2015   ... announced the launch of the Post-Surgical Pain Management TRACKER, ... data products tracking usage trends in the medical device ... monthly access to data including treatment volumes, market share, ... manage the pain associated with joint surgery. ...
Breaking Biology News(10 mins):NXT-ID Patents Miniature, Low Power Wireless Magnetic Stripe 2NXT-ID Patents Miniature, Low Power Wireless Magnetic Stripe 3NXT-ID Patents Miniature, Low Power Wireless Magnetic Stripe 4Fingerprint Cards Receives Touch Fingerprint Sensor Order of SEK 110 Million 2Guidepoint Launches Post-Surgical Pain Management TRACKER 2Guidepoint Launches Post-Surgical Pain Management TRACKER 3
... the protein responsible for transporting nutrients to the eye ... age-related macular degeneration, a leading cause of vision loss ... the process by which compounds called lutein and zeaxanthin ... have suggested that high concentrations of these two dietary ...
... 28, 2008The 2008 American Society for Microbiology ... Award is presented to Vctor de Lorenzo, ... of the Spanish Research Council, Cantoblanco-Madrid, Spain. ... has exhibited exemplary leadership in the international ...
... to be physically active. The key to being active is ... exercise in maintaining fitness has created the idea that individuals ... if the inclination to engage in physical activity is itself ... suggest that the inclination to exercise may be strongly affected ...
Cached Biology News:Protein transports nutrients believed to protect against eye disease 2Protein transports nutrients believed to protect against eye disease 3American Society for Microbiology honors Victor de Lorenzo 2Can you be born a couch potato? 2Can you be born a couch potato? 3
Smac/DIABLO (CT) - IgG for Western Blotting, Host: Rabbit Family: Smac/DIABLO...
... Immunogen: purified recombinant human angiogenin ... . Physical form: Lyophilized ... solution in phosphate buffered saline. ... WB. Titertest values: ...
... entire pressurized perfusion system for small ... biophysics, electrochemistry, or general liquid-handling research ... as 100 microliters of precious drugs. ... in milliseconds from a single tip. ...
Request Info...
Biology Products: